Home › Therapeutic areas › Oncology › Acute Myeloid Leukemia
Acute Myeloid Leukemia (16 companies)
Companies with an active program in Acute Myeloid Leukemia.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ACRV | Acrivon Therapeutics | GI/HepatologyOncology Rare | 1 | Phase 2 | $69.0M | 9 |
| ALLO | Allogene Therapeutics | ImmunologyOncology Rare | 1 | Phase 2 | $360M | 10 |
| APVO | Aptevo Therapeutics | Oncology | 1 | Phase 1 | $2.2M | 8 |
| BMEA | Biomea Fusion | MetabolicOncology | 1 | Phase 2 | $41.1M | 4 |
| CGEM | Cullinan Therapeutics | HematologyImmunology+2 Rare | 1 | NDA Submitted | $728M | 10 |
| GERN | Geron | Oncology | 1 | Approved | $638M | 3 |
| INAB | IN8bio | ImmunologyOncology | 1 | Phase 1 | $10.0M | 4 |
| KURA | Kura Oncology | MetabolicOncology | 1 | Approved | $647M | 12 |
| MRKR | Marker Therapeutics | Oncology | 1 | Phase 1 | $14.8M | 4 |
| MBRX | Moleculin Biotech | Oncology | 1 | Phase 2 | — | 8 |
| OMER | Omeros | HematologyNeurology+2 Rare | 1 | Approved | $1.22B | 6 |
| RXRX | Recursion Pharmaceuticals | Oncology | 1 | Phase 2 | $2.19B | 6 |
| SLS | SELLAS Life Sciences Group | Oncology | 2 | Phase 3 | $1.70B | 9 |
| SNDX | Syndax Pharmaceuticals | ImmunologyOncology Rare | 1 | Approved | $852M | 7 |
| TLX | Telix Pharmaceuticals | Oncology | 1 | Approved | $3.27B | 25 |
| HURA | TuHURA Biosciences | Oncology | 1 | Phase 3 | $104M | 4 |
No companies match.